Related references
Note: Only part of the references are listed.Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins
Farnaz Khodabakhsh et al.
PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY (2021)
Antibody alternative formats: antibody fragments and new frameworks
Olivier Kitten et al.
M S-MEDECINE SCIENCES (2020)
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models
Myriam Fabre et al.
CLINICAL CANCER RESEARCH (2020)
Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life
Fabian Brandl et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers
Andre L. B. Bitencourt et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Current strategies in extending half-lives of therapeutic proteins
Rahela Zaman et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Roman Kholodenko et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules
Oliver Seifert et al.
MABS (2019)
Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins
Fabian Brandl et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Pharmacokinetics of protein and peptide conjugates
Brandon Bumbaca et al.
DRUG METABOLISM AND PHARMACOKINETICS (2019)
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Adam Bates et al.
ANTIBODIES (2019)
Current progress in innovative engineered antibodies
William R. Strohl
PROTEIN & CELL (2018)
Aligning physics and physiology: Engineering antibodies for radionuclide delivery
Wen-Ting K. Tsai et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2018)
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis
Duncan B. Richards et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Antibody Engineering for Pursuing a Healthier Future
Abdullah F. U. H. Saeed et al.
FRONTIERS IN MICROBIOLOGY (2017)
Half-life extended biotherapeutics
Roland E. Kontermann
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
In vivo imaging with antibodies and engineered fragments
Amanda C. Freise et al.
MOLECULAR IMMUNOLOGY (2015)
High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation
Claudia T. Mendler et al.
MABS (2015)
Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties
Oliver Seifert et al.
MOLECULAR CANCER THERAPEUTICS (2014)
PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins
Martin Schlapschy et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
A novel long-acting human growth hormone fusion protein (vrs-317): enhanced in vivo potency and half-life
Jeffrey L. Cleland et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Strategies for extended serum half-life of protein therapeutics
Roland E. Kontermann
CURRENT OPINION IN BIOTECHNOLOGY (2011)
Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer
Yan-Shan Huang et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2010)
Antibody fragments Hope and hype
Aaron L. Nelson
MABS (2010)
Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose
Nathan C. Geething et al.
PLOS ONE (2010)
Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives
Roland Stork et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
Volker Schellenberger et al.
NATURE BIOTECHNOLOGY (2009)
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
D. Schoenfeld et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies
Roland Stork et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist - Sustained release of a local antiinflammatory therapeutic
Mohammed F. Shamji et al.
ARTHRITIS AND RHEUMATISM (2007)
Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries
P Amstutz et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment
Tove Olafsen et al.
NATURE PROTOCOLS (2006)
Protein PEGylation decreases observed target association rates via a dual blocking mechanism
S Kubetzko et al.
MOLECULAR PHARMACOLOGY (2005)
Improving protein pharmacokinetics by genetic fusion to simple amino acid sequences
P Alvarez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Share Paper
